Skip to main content

Ophthalmic Drugs Market Growth & Strategy Framework To 2020

In December 2017, Spark Therapeutics received Food and Drug Administration (FDA) approval for the first gene therapy drug in the ophthalmic market-Luxturna (voretigene neparvovec-rzyl). The drug is indicated for ophthalmic diseases associated with RPE65 gene mutation, such as retinitis pigmentosa and Leber’s congenital amaurosis.

Download Free PDF Sample  - https://www.radiantinsights.com/research/ophthalmic--drugs-market/request-sample

Increasing number of strategic mergers, acquisitions, and collaborations make the market for ophthalmic drugs a highly competitive space. However, there is ample scope for consolidation. Premium services and high-volume ancillary value-added businesses deliver supplementary benefits to customers and attract investments in the market. The reimbursement policies for ophthalmic treatment form a diversifying factor in the market.

Companies are constantly launching new products to expand their product portfolio and to attain higher share. For instance, in July 2019, Bausch & Lomb Incorporated announced launch of Ocuvite, an eye vitamin supplement to strengthen the macula for the U.S. market.

Due to increasing awareness of ophthalmic disorders and surge in the demand of these products, ophthalmic drug manufacturers are expanding their presence in the emerging economies by supporting various awareness campaigns in different regions. For instance, in 2016, Alcon announced their support to a public awareness program, Think About Your Eyes. The company committed USD 4 million to support this initiative and to promote awareness pertaining to vision care.

Browse Full Report With TOC  - https://www.radiantinsights.com/research/ophthalmic--drugs-market

Further key findings from the study suggest:

• Anti-VEGF agents dominated the drug class segment in 2019 and is anticipated to register the fastest CAGR of 6.7% over the forecast period

• Retinal disorder held the largest market share in 2019 due to rising prevalence of diabetic retinopathy

• In 2019, macular degeneration was the largest retinal disorder segment and diabetic retinopathy was the fastest growing segment

• Eye drops held the leading ophthalmic drugs market share in 2019 and is projected to witness the highest CAGR during the forecast period as it is the most preferred form of drug delivery used for treating ocular diseases such as acute allergies, corneal ulcers, and glaucoma

Comments

Popular posts from this blog

Functional Tea Market is expected to boost the growth of the market over the forecast period.

Functional Tea refers to a series of teas that can contribute to bodily functions. In 2019, the market size of Functional Tea is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period. Download Request sample copy -  https://www.innovationmarketresearch.com/market-reports/functional-tea-market/request-sample In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Functional Tea. This report studies the global market size of Functional Tea, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia). This study presents the Functional Tea sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sal...

Atherectomy Devices Industry Landscape & Scope Till, 2014 - 2025.

Asia pacific can be a potential market for atherectomy devices since countries such as India and china possess the largest number of cardiac patients with an annual incidence of 7 million strokes. Tobacco consumption is rapidly increasing in south Asian countries in conjunction with economic expansion increasing their risk of artery diseases. Reduction of abdominal obesity through lifestyle measures can improve all components of the metabolic syndrome and likely delay the development of both diabetes and atherosclerosis. Beyond lifestyle intervention, optimal management of risk factors to evidence-based targets is essential. Download Free Sample -  https://www.millioninsights.com/industry-reports/atherectomy-devices-market-size/request-sample High awareness of health problems caused due to change in lifestyle and optimal management of risk factors can improve the metabolic syndrome and likely reduce the development of both diabetes and atherosclerosis and hence reducing the de...

What are the land and construction requirements to start an Adipic Acid (CAS 124-04-9) manufacturing plant?

  Adipic acid or hexanedioic acid is the most important dicarboxylic acid with the formula (CH2)4(COOH)2. It is produced industrially by the oxidation of cyclohexanone and cyclohexanol with nitric acid. Adipic acid is one of the most important monomers, predominantly as a precursor for the production of nylon 66. The analysts forecast the global adipic acid market to exhibit a CAGR of 4.2% during the period 2019-2024. The report covers the present scenario and the growth prospects of the global adipic acid for 2019-2024. To calculate the market size, the report considers the adipic acid sales volume and revenue. Download Free Sample  -  https://www.radiantinsights.com/research/adipic-acid-cas-124-04-9-market/request-sample The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to...